Saccharide analog, 2‐deoxy‐ d ‐glucose enhances 4‐1BB‐mediated antitumor immunity via PD‐L1 deglycosylation

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology

(2019) Hyun Lee et al.   MOLECULES

Rational design of anti-GITR-based combination immunotherapy

(2019) Roberta Zappasodi et al.   NATURE MEDICINE

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy

(2019) Heng-Huan Lee et al.   CANCER CELL

Interferon Signaling is Diminished with Age and is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer

(2019) Jaclyn Sceneay et al.   Cancer Discovery

Mechanisms Controlling PD-L1 Expression in Cancer

(2019) Jong-Ho Cha et al.   MOLECULAR CELL

4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and other Intracranial Cancers

(2019) Karolina I. Woroniecka et al.   CLINICAL CANCER RESEARCH

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

(2018) Chia-Wei Li et al.   CANCER CELL

Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27–Dependent Pathway

(2018) Todd Bartkowiak et al.   CLINICAL CANCER RESEARCH

Immunotherapeutic interventions of Triple Negative Breast Cancer

(2018) Zehuan Li et al.   Journal of Translational Medicine

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

(2018) Jong-Ho Cha et al.   MOLECULAR CELL

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Coinhibitory Pathways in Immunotherapy for Cancer

(2016) Susanne H. Baumeister et al.   Annual Review of Immunology

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape

(2016) S.-O. Lim et al.   CANCER RESEARCH

Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives

(2016) Michael B. Atkins et al.   JNCI-Journal of the National Cancer Institute

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives

(2016) Michael B. Atkins et al.   JNCI-Journal of the National Cancer Institute

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Dissecting the Heterogeneity of Triple-Negative Breast Cancer

(2012) Otto Metzger-Filho et al.   JOURNAL OF CLINICAL ONCOLOGY

4-1BB signaling beyond T cells

(2011) Dass S Vinay et al.   Cellular & Molecular Immunology

Science gone translational: the OX40 agonist story

(2011) Andrew D. Weinberg et al.   IMMUNOLOGICAL REVIEWS

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting cancer metabolism: a therapeutic window opens

(2011) Matthew G. Vander Heiden   NATURE REVIEWS DRUG DISCOVERY

Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: Present status and future prospects

(2009) BS Dwarakanath et al.   Journal of Cancer Research and Therapeutics

Basal-Like Breast Cancer: A Critical Review

(2008) Emad A. Rakha et al.   JOURNAL OF CLINICAL ONCOLOGY